BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 195 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is 0.69 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $23,668,286 | -28.4% | 2,837,924 | -1.4% | 0.04% | -32.8% |
Q4 2022 | $33,044,342 | -1.0% | 2,878,427 | +8.6% | 0.06% | -1.7% |
Q3 2022 | $33,385,000 | +8.2% | 2,649,616 | -9.2% | 0.06% | +13.5% |
Q2 2022 | $30,864,000 | -33.2% | 2,917,209 | +2.7% | 0.05% | -14.8% |
Q1 2022 | $46,201,000 | +17.4% | 2,841,405 | +0.0% | 0.06% | +29.8% |
Q4 2021 | $39,351,000 | -4.0% | 2,841,230 | -0.4% | 0.05% | -6.0% |
Q3 2021 | $40,974,000 | -17.6% | 2,851,384 | -9.3% | 0.05% | -15.3% |
Q2 2021 | $49,699,000 | +61.5% | 3,143,485 | +3.9% | 0.06% | +51.3% |
Q1 2021 | $30,770,000 | – | 3,025,606 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |